The legacy of Viagra and its impact on the pharmaceutical sector presents a challenging question regarding its continued appeal as an investment. Initially a remarkable success, generating vast revenues, generic competition has substantially eroded earnings . While leading pharmaceutical firms maintain patents on related therapies and explore new f

The trajectory of companies tied to flagship drugs like Viagra presents a complex investment scenario . While the initial surge of copyright, fueled by Viagra's unprecedented popularity, generated substantial returns, the patent expiration in key markets has introduced significant volatility. Investors are now assessing the consequences of lower-co